Repositioning Candidate Details
| Candidate ID: | R1438 |
| Source ID: | DB12240 |
| Source Type: | approved; investigational |
| Compound Type: | biotech |
| Compound Name: | Polatuzumab vedotin |
| Synonyms: | Polatuzumab vedotin; polatuzumab vedotin-piiq |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Polatuzumab vedotin is a CD79b specific antibody conjugated to the antineoplastic agent monomethyl auristatin E. This medication was granted accelerated FDA approval on 10 June 2019. |
| CAS Number: | 1313206-42-6 |
| Molecular Weight: | |
| DrugBank Indication: | This medication is indicated to treat adults with relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab that has returned of progressed after 2 or more previous therapies. |
| DrugBank Pharmacology: | The binding of the unconjugated drug to microtubules in B cells leads to a number of immunosuppressant adverse effects including neutropenia and thrombocytopenia. The incidence of peripheral neuropathy also increases with increasing doses and time exposed to the drug. Polatuzumab vedotin does not prolong the QTc interval. |
| DrugBank MoA: | Polatuzumab vedotin is an antibody targeted to CD79b conjugated to the antineoplastic agent monomethyl auristatin E (MMAE). The antibody binds to CD79b on the surface of B cells, causing the conjugate to be endocytosed. Once inside the cell, lysosomal proteases cleave the link between MMAE and the antibody allowing MMAE to bind to microtubules, inhibit cell division, and induce apoptosis. |
| Targets: | B-cell antigen receptor complex-associated protein beta chain |
| Inclusion Criteria: | Therapeutic strategy associated |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|